148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
16 citations
,
January 2022 in “International journal of molecular sciences” This review summarizes the influences of lifestyle factors such as smoking, alcohol, and diet on the pathogenesis of alopecia areata but reports no new clinical results.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
31 citations
,
July 2021 in “ImmunoTargets and therapy” This review compiles current evidence on the molecular mechanisms, etiologies, and targeted immunotherapies for alopecia areata and reports no new experimental results, emphasizing the need for further research to manage the disease.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” This study suggests that the prevalence of alopecia areata in the US remains similar to high estimates from the 1970s, with significant implications for quality of life.
6 citations
,
March 2020 in “Jornal de Pediatria” This study found that inflammatory dermatoses, especially atopic dermatitis, were the most common pediatric skin conditions at a Brazilian reference center, highlighting different patterns compared to adult skin disorders.
86 citations
,
January 2020 in “British Journal of Dermatology” This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.
45 citations
,
April 2019 in “International Immunology” This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.
60 citations
,
April 2018 in “Clinical, cosmetic and investigational dermatology” This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.
37 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that black and Hispanic women had higher odds of self-reported alopecia areata compared to white women, highlighting potential racial disparities in the condition's occurrence.
34 citations
,
October 2017 in “Archivos Argentinos De Pediatria” This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
162 citations
,
October 2014 in “Autoimmunity reviews” This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.
44 citations
,
August 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.
106 citations
,
January 2013 in “Clinical and Developmental Immunology” This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.
109 citations
,
May 2011 in “Dermatologic Therapy” This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.
141 citations
,
March 2011 in “Journal of Dermatology” This study in Japan found varying prevalence of skin disorders, with atopic dermatitis common in children and tinea pedis in the elderly, and observed gender differences in disease susceptibility.
275 citations
,
November 2002 in “International Journal of Dermatology” This study found that among an Asian population with alopecia areata, commonly first episodes occurred before age 40, with severe cases linked to psychological effects and treatments showing significant regrowth.
65 citations
,
September 1999 in “The Journal of Dermatology” In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.
